阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂、血尿酸的影响-中国药房

阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂、血尿酸的影响

请在关注微信后，向客服人员索取文件

篇名：	阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂、血尿酸的影响
TITLE：
摘要：	目的：探讨阿托伐他汀联合别嘌醇对高脂血症合并高尿酸血症患者血脂和血尿酸（UA）的影响。方法： 90例高脂血症合并高尿酸血症患者随机均分为A、B、C组。A组患者给予别嘌醇片0.1 g，口服，每日1次+阿托伐他汀钙片30 mg，口服，每日1次；B组患者给予阿托伐他汀钙片（用法用量同A组）；C组患者给予别嘌醇片（用法用量同A组）。各组疗程均为4周。观察各组患者治疗前后三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、UA、尿素氮（BUN）、丙氨酸转氨酶（ALT）和肌酸磷酸激酶（CK）水平及不良反应发生情况。结果：治疗后，各组患者TG、TC、LDL水平均显著低于同组治疗前，且A、B组低于C组，差异均有统计学意义（P＜0.05）；各组患者UA水平均显著低于同组治疗前，且A、B组低于C组，A组低于B组，差异均有统计学意义（P＜0.05）；A、B组患者ALT水平、各组患者CK水平和A、C组患者BUN水平均显著高于同组治疗前，且A、B组CK水平高于C组，A组高于B组，差异均有统计学意义（P＜0.05）。各组患者不良反应发生率比较，差异均无统计学意义（P＞0.05）。结论：阿托伐他汀联合别嘌醇可显著降低高脂血症合并高尿酸血症患者血脂、UA水平，且安全性较好。
ABSTRACT：	OBJECTIVE：To explore the effects of atorvastatin combined with allopurinol on blood lipid and blood uric acid in patients with hyperlipidemia and hyperuricemia. METHODS：90 patients with hyperlipidemia and hyperuricemia were randomly divided into group A， group B and group C. Group A was orally given 0.1 g Allopurinol tablet， once a day+30 mg Atorvastatin calcium tablet， once a day. Group B was given Atorvastatin calcium tablet （the same dose with group A）. Group C was given Allopurinol tablet （the same dose with group A）. The treatment course for all groups was 4 weeks. TG， TC， LDL， HDL， UA， BUN， ALT and CK before and after treatment， and incidence of adverse reactions in all groups were observed. RESULTS：After treatment， TG， TC and LDL in all groups were significantly lower than before， group A and B were lower than group C， the differences were statistically significant （P＜0.05）； UA in all groups was significantly lower than before， group A and B were lower than group C， group A was lower than group B， the differences were statistically significant（P＜0.05）； ALT in group A and B， CK in all groups and BUN levels in group A and group C were significantly higher than before， CK in group A and group B higher than group C， group A was higher than group B， the differences were statistically significant（P＜0.05）. And there was no significant difference in the incidence of adverse reactions among all groups（P＞0.05）. CONCLUSIONS：Atorvastatin combined with allopurinol can significantly reduce the blood lipid and blood uric acid levels of patients， with good safety.
期刊：	2016年第27卷第12期
作者：	陆勤宣，梅伟红
AUTHORS：	LU Qinxuan，MEI Weihong
关键字：	阿托伐他汀；别嘌醇；高脂血症合并高尿酸血症；血脂；血尿酸
KEYWORDS：	Atorvastatin； Allopurinol； Hyperlipoidemia and Hyperuricemia； Blood lipid； Blood uric acid
阅读数：	853 次
本月下载数：	2 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！